Structure Therapeutics (NASDAQ:GPCR) Shares Gap Up to $39.64

Structure Therapeutics Inc. (NASDAQ:GPCR) gapped up before the market opened on Thursday . The stock had previously closed at $39.64, but opened at $41.00. Structure Therapeutics shares last traded at $40.08, with a volume of 46,563 shares trading hands.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on GPCR. Cantor Fitzgerald restated an “overweight” rating and issued a $65.00 target price on shares of Structure Therapeutics in a research note on Thursday, August 15th. JPMorgan Chase & Co. initiated coverage on Structure Therapeutics in a research report on Tuesday, May 21st. They set an “overweight” rating and a $65.00 price objective for the company. BMO Capital Markets boosted their target price on shares of Structure Therapeutics from $83.00 to $100.00 and gave the company an “outperform” rating in a report on Friday, June 7th. Finally, JMP Securities decreased their price target on shares of Structure Therapeutics from $91.00 to $86.00 and set a “market outperform” rating for the company in a research note on Friday, August 9th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $84.63.

Structure Therapeutics Trading Up 1.5 %

The firm has a fifty day moving average of $39.54 and a 200 day moving average of $40.43. The company has a market capitalization of $1.88 billion, a P/E ratio of -51.48 and a beta of -3.52.

Structure Therapeutics (NASDAQ:GPCR) last issued its earnings results on Thursday, August 8th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.05. Sell-side analysts anticipate that Structure Therapeutics Inc. will post -0.94 EPS for the current fiscal year.

Institutional Investors Weigh In On Structure Therapeutics

Hedge funds have recently modified their holdings of the business. Raymond James & Associates bought a new position in shares of Structure Therapeutics during the 4th quarter valued at approximately $233,000. New York State Common Retirement Fund purchased a new stake in shares of Structure Therapeutics in the fourth quarter worth $277,000. Russell Investments Group Ltd. bought a new stake in shares of Structure Therapeutics during the 4th quarter valued at $1,157,000. Natixis Advisors L.P. purchased a new position in shares of Structure Therapeutics during the 4th quarter valued at $634,000. Finally, M&T Bank Corp purchased a new position in shares of Structure Therapeutics during the 4th quarter valued at $596,000. Institutional investors own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.